Gastrointestinal Cancers

Gastrointestinal (GI) malignancies, including cancers of the esophagus, stomach, liver, gallbladder, pancreas, and colorectum, represent a major global health burden with high mortality rates. The development of novel, more effective therapeutic strategies is crucial. At Alfa Cytology, our team of renowned experts has been at the forefront of exploring the therapeutic potential of poly(ADP-ribose) polymerase (PARP) inhibitors in the treatment of these devastating GI cancers.

PARP as a Therapeutic Target for Gastrointestinal Cancer

PARP are a family of proteins that play a crucial role in various cellular processes, including DNA repair, gene expression regulation, and cell death. In the context of gastrointestinal (GI) cancers, PARP enzymes have been extensively studied for their potential involvement in cancer development and progression. For example, in gastric cancer, a subset of tumors may have deficiencies in HR repair pathways, making them more susceptible to PARP inhibition.

Fig. 1 PARP inhibitors in gastric cancer. (Wang Y., et al. 2021)

PARP Inhibitor Development for Gastrointestinal Cancers

The promising results of PARPi in other cancer types, such as breast, ovarian, and prostate cancer, have prompted researchers to investigate the therapeutic potential of these targeted agents in the context of GI malignancies. PARP inhibitors are being studied in combination with other targeted therapies, chemotherapies, and immunotherapies for GI cancers.

Our Services

At Alfa Cytology, our multifaceted expertise in PARP biology, drug development, and biomarker discovery positions them as a valuable partner in accelerating the advancement of novel PARP inhibitor-based therapies for gastrointestinal cancers.

By Molecule Type

By Disease

Our Cutting-Edge Technologies and Innovative Service Offerings

Our services leverage cutting-edge technologies and innovative platforms to accelerate PARP inhibitor development.

Advanced Biomarker Identification

Utilizing state-of-the-art genomic profiling and bioinformatics tools to identify novel biomarkers that can help expand the eligible patient population for PARP inhibitor therapy.

High-Throughput Screening (HTS)

Leveraging state-of-the-art HTS platforms, we efficiently screen compound libraries to identify potential PARP inhibitors.

Structure-Based Drug Design (SBDD)

Our SBDD approach utilizes molecular modeling and computational simulations to design potent and selective inhibitors with enhanced therapeutic efficacy.

Preclinical Modeling and Screening

Leveraging innovative in vitro and in vivo preclinical models to evaluate the efficacy of PARP inhibitors, both as monotherapies and in combination with other targeted agents.

At Alfa Cytology, we are committed to advancing the field of gastrointestinal cancer treatment through the development of cutting-edge PARP inhibitor therapies. If you are interested in exploring our services or collaborating on PARP inhibitor research, please don't hesitate to contact us. We are eager to discuss how we can support your research efforts and contribute to the ongoing progress in gastrointestinal cancer care.

For research use only. Not intended for any clinical use.